HC Wainwright Has Negative Outlook for Korro Bio Q1 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Equities research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of Korro Bio in a research note issued on Thursday, March 20th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.54) per share for the quarter, down from their prior estimate of ($2.45). HC Wainwright currently has a “Buy” rating and a $115.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.33) by $0.07. The company had revenue of $2.27 million for the quarter.

Other research analysts have also issued reports about the stock. Royal Bank of Canada reduced their price target on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, March 19th. Oppenheimer started coverage on Korro Bio in a research note on Friday, January 10th. They issued an “outperform” rating and a $155.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $142.57.

Korro Bio Trading Down 15.2 %

Korro Bio stock opened at $20.38 on Monday. Korro Bio has a 1-year low of $18.50 and a 1-year high of $98.00. The firm has a market capitalization of $191.35 million, a PE ratio of -2.17 and a beta of 2.13. The firm’s 50 day simple moving average is $29.27 and its 200 day simple moving average is $41.09.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Deep Track Capital LP lifted its stake in Korro Bio by 2.9% during the fourth quarter. Deep Track Capital LP now owns 874,614 shares of the company’s stock worth $33,297,000 after purchasing an additional 24,614 shares during the last quarter. Alliancebernstein L.P. bought a new stake in Korro Bio in the 4th quarter worth approximately $26,870,000. Driehaus Capital Management LLC boosted its stake in Korro Bio by 220.3% in the fourth quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company’s stock worth $18,841,000 after buying an additional 340,410 shares in the last quarter. Point72 Asset Management L.P. grew its position in Korro Bio by 11.0% during the fourth quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company’s stock valued at $18,806,000 after acquiring an additional 49,147 shares during the last quarter. Finally, Tri Locum Partners LP grew its position in Korro Bio by 125.3% during the fourth quarter. Tri Locum Partners LP now owns 144,216 shares of the company’s stock valued at $5,490,000 after acquiring an additional 80,202 shares during the last quarter. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).